Accepted Manuscript

Syntheses of cytotoxic novel arctigenin derivatives bearing halogen and alkyl groups on aromatic rings

Satoshi Yamauchi, Tuti Wukirsari, Yoshiaki Ochi, Hisashi Nishiwaki, Kosuke Nishi, Takuya Sugahara, Koichi Akiyama, Taro Kishida

PII:	S0960-894X(17)30683-2
DOI:	http://dx.doi.org/10.1016/j.bmcl.2017.06.070
Reference:	BMCL 25104
To appear in:	Bioorganic & Medicinal Chemistry Letters
Received Date:	16 May 2017
Revised Date:	25 June 2017
Accepted Date:	26 June 2017



Please cite this article as: Yamauchi, S., Wukirsari, T., Ochi, Y., Nishiwaki, H., Nishi, K., Sugahara, T., Akiyama, K., Kishida, T., Syntheses of cytotoxic novel arctigenin derivatives bearing halogen and alkyl groups on aromatic rings, *Bioorganic & Medicinal Chemistry Letters* (2017), doi: http://dx.doi.org/10.1016/j.bmcl.2017.06.070

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Syntheses of cytotoxic novel arctigenin derivatives bearing halogen and alkyl groups on aromatic rings

Satoshi Yamauchi^{a,b}*, Tuti Wukirsari^a, Yoshiaki Ochi,^a Hisashi Nishiwaki^a,

Kosuke Nishi^a, Takuya Sugahara,^{a,b} Koichi Akiyama,^c Taro Kishida^{a,b}

^aGraduate School of Agriculture, Ehime University, 3-5-7 Tarumi, Matsuyama, Ehime

790-8566, Japan

^bSouth Ehime Fisheries Research Center, 1289-1 Funakoshi, Ainan, Ehime 798-4292,

Japan

^cAdvanced Research Support Center (ADRES), Ehime University, 3-5-7 Tarumi,

Matsuyama, Ehime 790-8566, Japan

To whom correspondence should be addressed. Tel: +81-89-946-9846; Fax:

+81-89-977-4364; E-mail: syamauch@agr.ehime-u.ac.jp,

yamauchi.satoshi.mm@ehime-u.ac.jp

ABSTRACT

The new lignano-9,9'-lactones (α , β -dibenzyl- γ -butyrolactone lignans), which showed the higher cytotoxicity than arctigenin, were synthesized. The well-known cytotoxic arctigenin showed activity against HL-60 cells (EC₅₀ = 12 µM), however, it was inactive against HeLa cells (EC₅₀ > 100 µM). The synthesized (3,4-dichloro, 2'-butoxy)-derivative **55** and (3,4-dichloro, 4'-butyl)-derivative **66** bearing the lignano-9,9'-lactone structures showed the EC₅₀ values of 10 µM and 9.4 µM against HL-60 cells, respectively. Against HeLa cells, the EC₅₀ value of the derivative **66** was 27 µM. By comparing the activities with the corresponding 9,9'-epoxy structure (tetrahydrofuran compounds), the importance of the lactone structure of **55** and **66** for the higher activities was shown. The substituents on the aromatic ring of the lignano-9,9'-lactones affected the cytotoxicity level, observing more than 10-fold difference.

Key words: lignan; arctigenin; matairesinol; γ -butyrolactone; lignano-9,9'-lactone; α , β -dibenzyl- γ -butyrolactone

The naturally occurring (8*R*,8'*R*)-arctigenin (1) bearing a lignano-9,9'-lactone was isolated from fruits of *Arctium lappa* and phagocytic activity on leulemia cells have been reported.¹ It was recently found that *Jurinea mollis* is a rich source of (8*R*,8'*R*)-arctigenin (1).² The mechanism of cytotoxicity,^{3,4} the activity against multidrug resistant cancer cells,⁵ and attenuation of learning and memory deficits⁶ have been examined. The research on the arctigenin derivatives have also been continued.⁷⁻⁹ Matairesinols (**2**, **3**) bearing similar structure to arctigenin are dietary lignano-9,9'-lactones and contained in vegetables (Figure 1).¹⁰ The IgE-suppressive activity¹¹ and immunomodulatory activity¹² of (-)-matairesinol have been reported.



Figure 1. Structures of (8R,8'R)-arctigenin (1), both enantiomers of matairesinol (2, 3), and (8R,8'R)-dihydroguaiaretic acid (4).

(8R,8'R)-Dihydroguaiaretic acid (4), which is a butane type lignan, is also a natural cytotoxic lignan containing butane type structure. We previously clarified the structure

containing stereochemistry-activity relationship of dihydroguaiaretic acid, discovering the compounds showing the higher activity than the natural compound **4** by preparing the benzene ring derivatives.¹³ As a first stage for this project, the cytotoxicities of **1-3** were compared to evaluate the effect of the lignano-9,9'-lactone structure on the activity using H-60 and HeLa cells. After this evaluation, the lignano-9,9'-lactones bearing different kinds of substituents on the benzene ring were synthesized, and then the structure-activity relationship was examined to develop the new lignano-9,9'-lactones showing the higher activity than the natural lignano-9,9'-lactones **1-3** against HL-60 and HeLa cells. The results of this project would contribute to the construction of chemical library of lignan and develop a new medicine based on the lignan structure.

We can find the synthetic reports of the optically active $\arctan^{14\cdot16}$ and (*R*)-3-benzyl-4-butanolide,^{17,18} which is a synthetic intermediate for the derivatives **5-46** (Table 2). In this experiment, all derivatives were synthesized by employing the previously described method^{19,20} with modification. The α -benzylation was applied to (*R*)-3-benzyl-4-butanolide to prepare **5-46** and (*R*)-3-arylmethyl-4-butanolide to prepare **52-75** (Table 3). The synthesis of the racemic compound **5** was reported. The NMR data of our synthetic (8*R*,8'*R*)-**5** agreed with those in the literature.^{21,22} The 9,9'-lactone structure were transformed to 9,9'-epoxy structure **76-99** (Table 3) by the previously described method.¹⁹ The α , β -unsaturated butyrolactones **49** and **50** were prepared from the corresponding aldol product from (*R*)-3-benzyl-4-butanolide by dehydration employing KHSO₄,²³ followed by separation of *E*- and *Z*-form. The *E*- and *Z*-forms were identified by ¹H-NMR data.²⁴ The differential NOE between 7-H and 8'-H

4

confirmed the *E* and *Z* structures. The benzyl ethers, which are the protective group for the phenolic group in the synthetic process, were cleaved by BBr_3^{25} to obtain **52**, **58**, **62**, **76**, **82**, **86** or BCl_3^{26} to obtain **68**, **69**, **92**, **93**. The hydrogenolysis using 5% Pd/C and H₂ was performed to get the other phenolic compounds. The synthetic method, NMR, and MS data were descried in the supporting information.

Compounds	EC_{50} (μ M±SD)		
	HL-60 cells	HeLa Cells	
(8 <i>R</i> ,8' <i>R</i>)-arctigenin (1)	12 ± 1.5	> 100	
(8R,8'R)-matairesinol (2)	74 ± 2.2	> 100	
(8 <i>S</i> ,8' <i>S</i>)-matairesinol (3)	> 100	> 100	
(8 <i>R</i> ,8' <i>R</i>)-dihydroguaiaretic acid (4)	26 ± 0.9	22 ± 4.1	

The activities of (8R,8'R)-arctigenin (1), (8R,8'R)-matairesinol (2), and (8S,8'S)-matairesinol (3) against HL-60 and HeLa cells were compared in Table 1. Against HL-60 cells, (8R,8'R)-arctigenin (1) exhibited the highest activity to show the EC₅₀ value of 12 μ M. In the case of matairesinol, (8R,8'R)-matairesinol (2), which was 6-fold less potent than that of (8R,8'R)-arctigenin (1), exhibited the enantiospecific activity. (8*S*,8'*S*)-Matairesinol (3) did not show the activity at 100 μ M. The cytotoxicities of all lignano-9,9'-lactones 1-3 against HeLa cells were not observed at 100 μ M. However, (8*R*,8'*R*)-dihydroguaiaretic acid (4), which is a butane type of lignan, was effective against both HL-60 and HeLa cells. It could be assumed that the lignano-9,9'-lactone structure is disadvantageous for the cytotoxicity against HeLa cells. We tried to improve the activity of the lignano-9,9'-lactone by syntheses of the

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				0			
4 7 7 No. R EC ₅₀ (µM±SD) No. R EC ₅₀ (µM±SD) HL<-60			3 2	8	8		
RECso (µM±SD) bNo.RECso (µM±SD) HL-60No.RECso (µM±SD) HL-60H6H77 ± 2.7284-OCF327 ± 5.1nt62-OH83 ± 1.8294-OCH2OCH371 ± 2.0nt72-OCH379 ± 6.6304- O(CH2)3CH323 ± 1.527 ± 4.782-OCF339 ± 1.6314-O(CH2)3CH323 ± 1.527 ± 4.792-OCF439 ± 1.6314-O(CH2)3CH3>100nt02-OCH2OCH376 ± 7.317% inhibition17% inhibition29 ± 4.522-OCH275 ± 9.3334-CF322 ± 1.029 ± 4.522-CH357 ± 3.0344-F57 ± 2.6nt32-CF337 ± 1.3354-CI36 ± 1.7nt32-CF337 ± 0.8373-O(CH2)3CH335 ± 3.5nt42-F72 ± 1.8363-OCH3, 4-OH93 ± 5.2nt52-CI37 ± 0.8373-O(CH2)3CH335 ± 3.5nt63-OH>1004-OH4-OH4-OH4-OH73-OCH366 ± 3.8393-O(CH2)3CH329% inhibition93-O(CH2)CH380 ± 9.44-O(CH2)3CH329% inhibition10093-O(CH2)CH381 ± 0.4413-CH3, 4-CH335 ± 5.1nt13-O(CH2)CH381 ± 0.4413-CH3, 4-CH335 ± 5.1nt13-O			4			•	0
No. R EC ₈₀ (μ M±SD) No. R EC ₅₀ (μ M±SD) HL-60 HL-60 <th></th> <th></th> <th>R_{56}</th> <th>,</th> <th>5-46</th> <th></th> <th></th>			R_{56}	,	5-46		
HL-60HL-60HL-60HL-60HeLaiH77 ± 2.7 284-OCF327 ± 5.1 nti2-OH83 ± 1.8 294-OCH2OCH371 ± 2.0 nti2-OCH379 ± 6.6 304-O(CH2)3CH323 ± 1.5 27 ± 4.7 i2-OCH376 ± 7.3 17% inhibition02-O(CH2OCH376 ± 7.3 17% inhibition02-O(CH2)GCH376 ± 7.3 17% inhibition100nt12-O(CH2)GCH375 ± 9.3 334-CF322 ± 1.0 29 ± 4.5 22-CH357 ± 3.0 344-F57 ± 2.6 nt32-CF337 ± 1.3 354-CI36 ± 1.7 nt32-CF337 ± 1.3 354-CI36 ± 1.7 nt32-CF337 ± 0.8 373-O(CH2)3CH335 ± 3.5 nt42-F72 ± 1.8 363-OCH34-OH $-$ 52-CI37 ± 0.8 373-O(CH2)3CH335 ± 3.5 nt63-OH>1004-OH $ -$ 73-OCH366 ± 3.8 393-O(CH2)3CH329% inhibition73-OCH380 ± 9.4 $4-O(CH2)3CH3$ 29% inhibition73-OCH380 ± 9.4 $4-O(CH2)3CH3$ 29% inhibition73-OCH380 ± 9.4 $4-O(CH2)3CH3$ 29% inhibition73-OCH381 ± 0.4 413-CH3, 4-CH335 ± 5.1 <td< th=""><th>No.</th><th>R</th><th>EC₅₀ (µM±SD)</th><th>No.</th><th>R</th><th>EC₅₀ (µM</th><th>(±SD)</th></td<>	No.	R	EC ₅₀ (µM±SD)	No.	R	EC ₅₀ (µM	(±SD)
\mathbf{F} \mathbf{H} 77 ± 2.7 28 $4 - \mathrm{OCF}_3$ 27 ± 5.1 \mathbf{nt} 5 $2 - \mathrm{OH}$ 83 ± 1.8 29 $4 - \mathrm{OCH}_2 \mathrm{OCH}_3$ 71 ± 2.0 \mathbf{nt} $2 - \mathrm{OCH}_3$ 79 ± 6.6 30 $4 - \mathrm{O(CH}_2)_3 \mathrm{CH}_3$ 23 ± 1.5 27 ± 4.7 3 $2 - \mathrm{OCF}_3$ 39 ± 1.6 31 $4 - \mathrm{O(CH}_2)_3 \mathrm{CH}_3$ 21 ± 1.5 27 ± 4.7 3 $2 - \mathrm{OCH}_2 \mathrm{OCH}_3$ 76 ± 7.3 17% 17% 100 \mathbf{nt} 1 $2 - \mathrm{O(CH}_2)_3 \mathrm{CH}_3$ 20 ± 1.1 32 $4 - \mathrm{CH}_5$ 44 ± 1.1 \mathbf{nt} 1 $2 - \mathrm{O(CH}_2)_6 \mathrm{CH}_3$ 75 ± 9.3 33 $4 - \mathrm{CF}_5$ 22 ± 1.0 29 ± 4.5 2 $2 - \mathrm{CH}_3$ 57 ± 3.0 34 $4 - \mathrm{F}$ 57 ± 2.6 \mathbf{nt} 3 $2 - \mathrm{CF}_3$ 37 ± 1.3 35 $4 - \mathrm{CI}$ 36 ± 1.7 \mathbf{nt} 4 $2 - \mathrm{F}$ 72 ± 1.8 36 $3 - \mathrm{OCH}_3$ 35 ± 3.5 \mathbf{nt} 5 $2 - \mathrm{CI}$ 37 ± 0.8 37 $3 - \mathrm{OCH}_3$ 35 ± 3.5 \mathbf{nt} 6 $3 - \mathrm{OH}$ >100 \mathbf{nt} $4 - \mathrm{OH}$ 38 $3 - \mathrm{OCH}_3$ 3100 \mathbf{nt} 7 $3 - \mathrm{OCH}_3$ 80 ± 9.4 $4 - \mathrm{O(CH}_2)_3 \mathrm{CH}_3$ 29% $\mathbf{nhibition}$ 7 $3 - \mathrm{OCH}_3$ 80 ± 9.4 $4 - \mathrm{O(CH}_2)_3 \mathrm{CH}_3$ 29% $\mathbf{nhibition}$ 7 $3 - \mathrm{OCH}_3$ <th></th> <th></th> <th>HL-60</th> <th></th> <th></th> <th>HL-60</th> <th>HeLa</th>			HL-60			HL-60	HeLa
52-OH 83 ± 1.8 294-OCH ₂ OCH ₃ 71 ± 2.0 nt2-OCH ₃ 79 ± 6.6 304-O(CH ₂) ₃ CH ₃ 23 ± 1.5 27 ± 4.7 32-OCF ₃ 39 ± 1.6 314-O(CH ₂) ₆ CH ₃ >100 nt02-OCH ₂ OCH ₃ 76 ± 7.3 17% inhibition 17% inhibition 17% inhibition02-O(CH ₂) ₃ CH ₃ 20 ± 1.1 324-CH ₃ 44 ± 1.1 nt12-O(CH ₂) ₆ CH ₃ 75 ± 9.3 334-CF ₃ 22 ± 1.0 29 ± 4.5 22-CH ₃ 57 ± 3.0 34 $4-F$ 57 ± 2.6 nt32-CF ₃ 37 ± 1.3 35 $4-Cl$ 36 ± 1.7 nt42-F 72 ± 1.8 36 $3-OCH_3, 4-OH$ 35 ± 3.5 nt52-Cl 37 ± 0.8 37 $3-O(CH_2)_3CH_3$ 35 ± 3.5 nt6 $3-OH$ >100 $4-OH$ $4-OH$ $4-OH$ $4-OH$ 7 $3-OCH_3$ 66 ± 3.8 39 $3-O(CH_2)_3CH_3$ 29% inhibition7 $3-OCH_3$ 80 ± 9.4 40 $3-O(CH_2)_3CH_3$ 29% inhibition7 $3-OCH_3$ 34 ± 3.7 40 $3-O(CH_2)_0-H$ 57 ± 5.8 nt7 $3-O(CH_2)_3CH_3$ 34 ± 3.7 40 $3-O(CH_2)_0-H$ 57 ± 5.8 nt7 $3-O(CH_2)_3CH_3$ 34 ± 3.7 41 $3-O(CH_2)_0-H$ 57 ± 5.8 nt7 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-O(CH_2)_0-H$ $57 \pm 5.$	5	Н	77 ± 2.7	28	4-OCF ₃	27 ± 5.1	nt
22-OCH379 ± 6.6304-O(CH2)3CH323 ± 1.527 ± 4.732-OCF339 ± 1.6314-O(CH2)6CH3>100nt02-OCH2OCH376 ± 7.3117% inhibition17% inhibition02-O(CH2)3CH320 ± 1.1324-CH344 ± 1.1nt12-O(CH2)6CH375 ± 9.3334-CF322 ± 1.029 ± 4.522-CH357 ± 3.0344-F57 ± 2.6nt32-CF337 ± 1.3354-CI36 ± 1.7nt42-F72 ± 1.8363-OCH3, 4-OH93 ± 5.2nt52-Cl37 ± 0.8373-O(CH2)3CH335 ± 3.5nt63-OH1004-OH4-OH173-OCH366 ± 3.833-O(CH2)3CH3>100nt73-OCH366 ± 3.833-O(CH2)3CH329% inhibition173-OCH366 ± 1.7403-O(CH2)0-CH335 ± 5.1nt73-O(CH2)3CH326 ± 1.7403-O(CH2)0-CH57 ± 5.8nt73-O(CH2)6CH381 ± 0.4413-CH3, 4-CH335 ± 5.1nt73-O(CH2)6CH381 ± 0.4413-CH3, 4-CH335 ± 5.1nt73-O(CH2)6CH381 ± 0.4413-CH3, 4-CH335 ± 5.1nt73-CH353 ± 8.3423-F, 4-F50 ± 3.7nt33-CF334 ± 1.9433-CI, 4-C	6	2-OH	83 ± 1.8	29	4-OCH ₂ OCH ₃	71 ± 2.0	nt
32-OCF3 39 ± 1.6 31 $4-O(CH_2)_6CH_3$ >100nt02-O(CH_2OCH_3 76 ± 7.3 32 $4-CH_5$ 44 ± 1.1 nt12-O(CH_2)_3CH_3 20 ± 1.1 32 $4-CF_3$ 22 ± 1.0 29 ± 4.5 22-CH_3 57 ± 9.3 33 $4-CF_3$ 22 ± 1.0 29 ± 4.5 3 $2-CF_3$ 57 ± 3.0 34 $4-F$ 57 ± 2.6 nt3 $2-CF_3$ 37 ± 1.3 35 $4-CI$ 36 ± 1.7 nt4 $2-F$ 72 ± 1.8 36 $3-OCH_3, 4-OH$ 93 ± 5.2 nt5 $2-CI$ 37 ± 0.8 37 $3-O(CH_2)_3CH_3$ 35 ± 3.5 nt6 $3-OH$ >100 $4-OH$ $4-OH$ 100 nt7 $3-OCH_3$ 66 ± 3.8 3 $3-O(CH_2)_3CH_3$ 2100 nt8 $3-OCF_3$ 34 ± 3.7 39 $3-O(CH_2)_3CH_3$ 29% inhibition9 $3-OCH_3CH_3$ 26 ± 1.7 40 $3-O(CH_2)O-4$ 57 ± 5.8 nt11 $3-O(CH_2)_3CH_3$ 26 ± 1.7 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt12 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt13 $3-O(CH_2)_6CH_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 14 $3-FF$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 15 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$	7	2-OCH ₃	79 ± 6.6	30	4- O(CH ₂) ₃ CH ₃	23 ± 1.5	27 ± 4.7
$2 - OCH_2OCH_3$ 76 ± 7.3 17% inhibition 0 $2 - O(CH_2)_3CH_3$ 20 ± 1.1 32 $4 - CH_3$ 44 ± 1.1 nt 1 $2 - O(CH_2)_3CH_3$ 75 ± 9.3 33 $4 - CF_3$ 22 ± 1.0 29 ± 4.5 2 $2 - CH_3$ 57 ± 3.0 34 $4 - F$ 57 ± 2.6 nt 3 $2 - CF_3$ 37 ± 1.3 35 $4 - CI$ 36 ± 1.7 nt 3 $2 - CF_3$ 37 ± 0.8 36 $3 - OCH_3$ 35 ± 3.5 nt 6 $3 - OH$ > 100 $4 - OH$ 3 ± 3.5 nt 7 $3 - OCH_3$ 66 ± 3.8 $3 - OCH_3 + 4 - OH$ 310 nt 7 $3 - OCH_3$ 80 ± 9.4 $3 - O(CH_2)_3CH_3$ > 100 nt 9 $3 - OCF_3$ 34 ± 3.7 39 $3 - O(CH_2)_3CH_3$ > 100 nt 7 $3 - O(CH_2)_3CH_3$ 26 ± 1.7 40 $3 - O(CH_2)_3CH_3$ 29% inhibition 9 $3 - O(CH_2)_3CH_3$ 26 ± 1.7 40 $3 - O(CH_2)O-4$ 57 ± 5.8 nt 13 $3 - O(CH_2)_6CH_3$ 81 ± 0.4 41 $3 - CH_3$ 35 ± 5.1 nt 13 $3 - CF_3$ 34 ± 1.9 43 $3 - CI, 4 - CI$ 19 ± 0.6 26 ± 3.8 3 $3 - CF_3$ 34 ± 1.9 43 $3 - CI, 4 - CI$ 19 ± 0.5 23 ± 3.8 3 $3 - CF_3$ 34 ± 1.9 45 $3 - CI, 4 - CI$ 19 ± 0.5 23 ± 3.8 3 $3 - CI_3$ 34 ± 1.9	8	$2-OCF_3$	39 ± 1.6	31	4-O(CH ₂) ₆ CH ₃	>100	nt
0 $2-O(CH_2)_3CH_3$ 20 ± 1.1 32 $4-CH_3$ 44 ± 1.1 nt1 $2-O(CH_2)_6CH_3$ 75 ± 9.3 33 $4-CF_3$ 22 ± 1.0 29 ± 4.5 2 $2-CH_3$ 57 ± 3.0 34 $4-F$ 57 ± 2.6 nt3 $2-CF_3$ 37 ± 1.3 35 $4-CI$ 36 ± 1.7 nt4 $2-F$ 72 ± 1.8 36 $3-OCH_3, 4-OH$ 93 ± 5.2 nt5 $2-CI$ 37 ± 0.8 37 $3-O(CH_2)_3CH_3$ 35 ± 3.5 nt6 $3-OH$ >100 $4-OH$ $4-OH$ 7 7 $3-OCH_3$ 66 ± 3.8 3 $3-O(CH_2)_3CH_3$ >100 nt7 $3-OCF_3$ 34 ± 3.7 39 $3-O(CH_2)_3CH_3$ >100 nt9 $3-OCF_3$ 80 ± 9.4 $4-O(CH_2)_3CH_3$ 29% inhibition $-4O(CH_2)_3CH_3$ 29% inhibition1 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-C(CH_2)O-4$ 57 ± 5.8 nt1 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt1 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 3 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 3 $3-CF_3$ 34 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 4 $3-F$ 75 ± 3.4 44 $2-CI, 4-CCH_3$ >100 nt7 $4-OH_3$ 67 ± 6.0 $5-O$	9	2-OCH ₂ OCH ₃	76 ± 7.3			17% inhibition	
1 $2 - O(CH_2)_6 CH_3$ 75 ± 9.3 33 $4 - CF_3$ 22 ± 1.0 29 ± 4.5 2 $2 - CH_3$ 57 ± 3.0 34 $4 - F$ 57 ± 2.6 nt3 $2 - CF_3$ 37 ± 1.3 35 $4 - Cl$ 36 ± 1.7 nt4 $2 - F$ 72 ± 1.8 36 $3 - OCH_3, 4 - OH$ 93 ± 5.2 nt5 $2 - Cl$ 37 ± 0.8 37 $3 - O(CH_2)_3 CH_3$ 35 ± 3.5 nt6 $3 - OH$ > 100 $4 - OH$ $4 - OH$ 100 nt7 $3 - OCH_3$ 66 ± 3.8 $3 - OCH_3, 4 - OCH_3$ > 100 nt8 $3 - OCF_3$ 34 ± 3.7 39 $3 - O(CH_2)_3 CH_3$ > 100 nt9 $3 - OCH_2 OCH_3$ 80 ± 9.4 $4 - O(CH_2)_3 CH_3$ > 100 nt10 $3 - O(CH_2)_3 CH_3$ 26 ± 1.7 40 $3 - O(CH_2)O - 4$ 57 ± 5.8 nt11 $3 - O(CH_2)_3 CH_3$ 26 ± 1.7 40 $3 - O(CH_2)O - 4$ 57 ± 5.8 nt12 $3 - O(CH_2)_3 CH_3$ 26 ± 1.7 40 $3 - O(CH_2)O - 4$ 57 ± 5.8 nt13 $3 - O(CH_2)_6 CH_3$ 81 ± 0.4 41 $3 - CH_3$ 35 ± 5.1 nt14 $3 - O(CH_2)_6 CH_3$ 81 ± 0.4 41 $3 - CH_3$ 35 ± 5.1 nt15 $3 - CH_3$ 53 ± 8.3 42 $3 - F, 4 - F$ 50 ± 3.7 nt15 $3 - CI_3$ 34 ± 1.9 43 $3 - CI, 4 - CI$ 19 ± 0.6 26 ± 3.8 1	10	2-O(CH ₂) ₃ CH ₃	20 ± 1.1	32	4-CH ₃	44 ± 1.1	nt
22-CH3 57 ± 3.0 344-F 57 ± 2.6 nt32-CF3 37 ± 1.3 354-Cl 36 ± 1.7 nt42-F 72 ± 1.8 36 $3-OCH3, 4-OH$ 93 ± 5.2 nt52-Cl 37 ± 0.8 37 $3-O(CH_2)_3CH_3$ 35 ± 3.5 nt6 $3-OH$ >100 $4-OH$ $4-OH$ $-0H$ 7 $3-OCH3$ 66 ± 3.8 $3-OCH_3, 4-OCH_3$ >100nt7 $3-OCH_3$ 66 ± 3.8 $3-O(CH_2)_3CH_3$ >100nt9 $3-OCH_2OCH_3$ 80 ± 9.4 $3-O(CH_2)_3CH_3$ >100nt9 $3-O(CH_2)_3CH_3$ 26 ± 1.7 40 $3-O(CH_2)O-4$ 57 ± 5.8 nt10 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt12 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 13 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 14 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 15 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 16 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt17 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	11	2-O(CH ₂) ₆ CH ₃	75 ± 9.3	33	4-CF ₃	22 ± 1.0	29 ± 4.5
32-CF3 37 ± 1.3 354-Cl 36 ± 1.7 nt42-F 72 ± 1.8 36 3 -OCH3, 4-OH 93 ± 5.2 nt52-Cl 37 ± 0.8 37 3 -OCH2)_3CH3 35 ± 3.5 nt6 3 -OH>100 4 -OH 4 -OH 35 ± 3.5 nt7 3 -OCH3 66 ± 3.8 3 -OCH3, 4-OCH3>100nt7 3 -OCH3 66 ± 3.8 3 -OCH2)_3CH3>100nt9 3 -OCH2OCH3 80 ± 9.4 4 -O(CH2)_3CH329% inhibition9 3 -O(CH2)AGH3 26 ± 1.7 40 3 -O(CH2)OH3 29% inhibition9 3 -O(CH2)_6CH3 81 ± 0.4 41 3 -CH3, 4 -CH3 35 ± 5.1 nt10 3 -O(CH2)_6CH3 81 ± 0.4 41 3 -CH3, 4 -CH3 35 ± 5.1 nt12 3 -OCF3 34 ± 1.9 43 3 -CI, 4 -CI 19 ± 0.6 26 ± 3.8 13 3 -CF3 34 ± 1.9 43 3 -CI, 4 -CI 19 ± 0.5 23 ± 3.8 14 3 -F 75 ± 3.4 44 2 -CI, 4 -CI 19 ± 0.5 23 ± 3.8 15 3 -CI 36 ± 1.9 45 3 -CI, 5 -CI 23 ± 1.9 17 ± 3.5 16 4 -OH 88 ± 4.1 46 3 -OCH3 44% inhibition	12	2-CH ₃	57 ± 3.0	34	4-F	57 ± 2.6	nt
42-F 72 ± 1.8 36 $3-OCH_3, 4-OH$ 93 ± 5.2 nt52-Cl 37 ± 0.8 37 $3-O(CH_2)_3CH_3$ 35 ± 3.5 nt6 $3-OH$ >100 $4-OH$ $4-OH$ 7 $3-OCH_3$ 66 ± 3.8 $30 - OCH_3, 4-OCH_3$ >100nt7 $3-OCH_3$ 66 ± 3.8 $30 - O(CH_2)_3CH_3$ >100nt9 $3-OCF_3$ 34 ± 3.7 39 $3-O(CH_2)_3CH_3$ >100nt9 $3-OCH_2OCH_3$ 80 ± 9.4 40 $3-O(CH_2)_3CH_3$ 29% inhibition9 $3-O(CH_2)_3CH_3$ 26 ± 1.7 40 $3-O(CH_2)O-4$ 57 ± 5.8 nt10 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt12 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt13 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 14 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 15 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 16 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt17 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	13	2-CF ₃	37 ± 1.3	35	4-Cl	36 ± 1.7	nt
52-Cl 37 ± 0.8 37 ± 0.8 37 ± 0.0 35 ± 3.5 nt63-OH>100 $4-OH$ $4-OH$ $38 + OCH_3$ >100nt73-OCH_3 66 ± 3.8 $3-OCH_3$ 34 ± 3.7 $39 + 3-O(CH_2)_3CH_3$ >100nt9 $3-OCH_2OCH_3$ 80 ± 9.4 $3-O(CH_2)_3CH_3$ >100nt9 $3-O(CH_2)_3CH_3$ 26 ± 1.7 $40 + 3-O(CH_2)_3CH_3$ 29% inhibition9 $3-O(CH_2)_3CH_3$ 26 ± 1.7 $40 + 3-O(CH_2)_3CH_3$ 35 ± 5.1 nt9 $3-O(CH_2)_3CH_3$ 26 ± 1.7 $41 + 3-O(CH_2)_3CH_3$ 35 ± 5.1 nt9 $3-O(CH_2)_3CH_3$ 26 ± 1.7 $41 + 3-O(CH_2)_3CH_3$ 35 ± 5.1 nt9 $3-O(CH_2)_3CH_3$ 34 ± 0.4 $41 + 3-O(H_3)$ 35 ± 5.1 nt10 $3-O(CH_2)_6CH_3$ 81 ± 0.4 $41 + 3-O(H_3)$ 35 ± 5.1 nt11 $3-O(CH_2)_6CH_3$ 81 ± 0.4 $41 + 3-CH_3$ 35 ± 5.1 nt12 $3-CF_3$ 34 ± 1.9 $43 + 3-CH_3$ $3-CH_3$ 26 ± 3.8 13 $3-CF_3$ 34 ± 1.9 $43 + 3-CH_3$ $3-CI_3$ 23 ± 3.8 14 $3-CH_3$ $3-CI_3$ 34 ± 1.9 $43 + 3-CI_3$ $3-CI_3$ 23 ± 3.8 15 $3-CI_3$ 36 ± 1.9 $45 + 3-CI_3$ $3-CI_3$ $100 + 1 \pm 3.5$ 16 $4-OH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	14	2-F	72 ± 1.8	36	3-OCH ₃ , 4-OH	93 ± 5.2	nt
6 $3 \cdot OH$ >100 $4 \cdot OH$ 7 $3 \cdot OCH_3$ 66 ± 3.8 36 ± 3.8 36 ± 3.8 38 $3 \cdot OCH_3$ >100nt8 $3 \cdot OCF_3$ 34 ± 3.7 39 $3 \cdot O(CH_2)_3CH_3$ >100nt9 $3 \cdot OCH_2OCH_3$ 80 ± 9.4 $4 \cdot O(CH_2)_3CH_3$ 29% inhibition10 $3 \cdot O(CH_2)_3CH_3$ 26 ± 1.7 40 $3 \cdot O(CH_2)O-44$ 57 ± 5.8 nt11 $3 \cdot O(CH_2)_6CH_3$ 81 ± 0.4 41 $3 \cdot CH_3$ 35 ± 5.1 nt12 $3 \cdot O(CH_2)_6CH_3$ 81 ± 0.4 41 $3 \cdot CH_3$ 35 ± 5.1 nt13 $3 \cdot O(CH_2)_6CH_3$ 81 ± 0.4 41 $3 \cdot CH_3$ 35 ± 5.1 nt14 $3 \cdot O(CH_2)_6CH_3$ 81 ± 0.4 41 $3 \cdot CH_3$ 35 ± 5.1 nt13 $3 \cdot O(CH_3)_6CH_3$ 34 ± 1.9 43 $3 \cdot CI, 4 \cdot CI$ 19 ± 0.6 26 ± 3.8 14 $3 \cdot F$ 75 ± 3.4 44 $2 \cdot CI, 4 \cdot CI$ 19 ± 0.5 23 ± 3.8 15 $3 \cdot CI$ 36 ± 1.9 45 $3 \cdot CI, 5 \cdot CI$ 23 ± 1.9 17 ± 3.5 16 $4 \cdot OH$ 88 ± 4.1 46 $3 \cdot OCH_3, 4 \cdot OCH_3$ >100 nt17 $4 \cdot OCH_3$ 67 ± 6.0 $5 \cdot OCH_3$ 44% inhibition	15	2-Cl	37 ± 0.8	37	3-O(CH ₂) ₃ CH ₃	35 ± 3.5	nt
45% inhibition38 $3-OCH_3$ >100nt7 $3-OCH_3$ 66 ± 3.8 38% inhibition 38% inhibition8 $3-OCF_3$ 34 ± 3.7 39 $3-O(CH_2)_3CH_3$ >100nt9 $3-OCH_2OCH_3$ 80 ± 9.4 $4-O(CH_2)_3CH_3$ 29% inhibition0 $3-O(CH_2)_3CH_3$ 26 ± 1.7 40 $3-O(CH_2)O-4$ 57 ± 5.8 nt21 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt22 $3-CH_3$ 53 ± 8.3 42 $3-F, 4-F$ 50 ± 3.7 nt23 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 24 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 25 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 36 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt7 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	16	3-ОН	>100		4-OH		
7 $3 - OCH_3$ 66 ± 3.8 38% inhibition8 $3 - OCF_3$ 34 ± 3.7 39 $3 - O(CH_2)_3CH_3$ >100 nt9 $3 - OCH_2OCH_3$ 80 ± 9.4 $4 - O(CH_2)_3CH_3$ 29% inhibition0 $3 - O(CH_2)_3CH_3$ 26 ± 1.7 40 $3 - O(CH_2)O-4$ 57 ± 5.8 nt1 $3 - O(CH_2)_6CH_3$ 81 ± 0.4 41 $3 - CH_3$ 35 ± 5.1 nt2 $3 - CH_3$ 53 ± 8.3 42 $3 - F, 4 - F$ 50 ± 3.7 nt3 $3 - CF_3$ 34 ± 1.9 43 $3 - CI, 4 - CI$ 19 ± 0.6 26 ± 3.8 44 $3 - F$ 75 ± 3.4 44 $2 - CI, 4 - CI$ 19 ± 0.5 23 ± 3.8 5 $3 - CI$ 36 ± 1.9 45 $3 - CI, 5 - CI$ 23 ± 1.9 17 ± 3.5 6 $4 - OH$ 88 ± 4.1 46 $3 - OCH_3, 4 - OCH_3$ >100 nt7 $4 - OCH_3$ 67 ± 6.0 $5 - OCH_3$ 44% inhibition		0	45% inhibition	38	3-OCH ₃ , 4-OCH ₃	>100	nt
8 $3-OCF_3$ 34 ± 3.7 39 $3-O(CH_2)_3CH_3$ >100nt9 $3-OCH_2OCH_3$ 80 ± 9.4 $4-O(CH_2)_3CH_3$ 29% inhibition0 $3-O(CH_2)_3CH_3$ 26 ± 1.7 40 $3-O(CH_2)O-4$ 57 ± 5.8 nt1 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt2 $3-CH_3$ 53 ± 8.3 42 $3-F, 4-F$ 50 ± 3.7 nt33 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 44 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 35 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 36 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt47 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	17	3-OCH ₃	66 ± 3.8			38% inhibition	
9 $3-OCH_2OCH_3$ 80 ± 9.4 $4-O(CH_2)_3CH_3$ 29% inhibition40 $3-O(CH_2)_3CH_3$ 26 ± 1.7 40 $3-O(CH_2)O-4$ 57 ± 5.8 nt41 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt42 $3-CH_3$ 53 ± 8.3 42 $3-F, 4-F$ 50 ± 3.7 nt43 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 44 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 45 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 46 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt	18	3-OCF ₃	34 ± 3.7	39	3-O(CH ₂) ₃ CH ₃	>100	nt
20 $3-O(CH_2)_3CH_3$ 26 ± 1.7 40 $3-O(CH_2)O-4$ 57 ± 5.8 nt 21 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt 22 $3-CH_3$ 53 ± 8.3 42 $3-F, 4-F$ 50 ± 3.7 nt 23 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 24 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 25 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 46 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt 77 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	19	3-OCH ₂ OCH ₃	80 ± 9.4		4-O(CH ₂) ₃ CH ₃	29% inhibition	
1 $3-O(CH_2)_6CH_3$ 81 ± 0.4 41 $3-CH_3, 4-CH_3$ 35 ± 5.1 nt2 $3-CH_3$ 53 ± 8.3 42 $3-F, 4-F$ 50 ± 3.7 nt3 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 44 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 25 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 46 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt77 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	20	3-O(CH ₂) ₃ CH ₃	26 ± 1.7	40	3-O(CH ₂)O-4	57 ± 5.8	nt
22 $3-CH_3$ 53 ± 8.3 42 $3-F, 4-F$ 50 ± 3.7 nt23 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 24 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 25 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 26 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt27 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	21	3-O(CH ₂) ₆ CH ₃	81 ± 0.4	41	3-CH ₃ , 4-CH ₃	35 ± 5.1	nt
23 $3-CF_3$ 34 ± 1.9 43 $3-CI, 4-CI$ 19 ± 0.6 26 ± 3.8 24 $3-F$ 75 ± 3.4 44 $2-CI, 4-CI$ 19 ± 0.5 23 ± 3.8 25 $3-CI$ 36 ± 1.9 45 $3-CI, 5-CI$ 23 ± 1.9 17 ± 3.5 26 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt27 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	22	3-CH ₃	53 ± 8.3	42	3-F, 4-F	50 ± 3.7	nt
24 $3-F$ 75 ± 3.4 44 $2-Cl, 4-Cl$ 19 ± 0.5 23 ± 3.8 25 $3-Cl$ 36 ± 1.9 45 $3-Cl, 5-Cl$ 23 ± 1.9 17 ± 3.5 26 $4-OH$ 88 ± 4.1 46 $3-OCH_3, 4-OCH_3$ >100nt27 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	23	3-CF ₃	34 ± 1.9	43	3-Cl, 4-Cl	19 ± 0.6	26 ± 3.8
25 $3-Cl$ 36 ± 1.9 45 $3-Cl$, $5-Cl$ 23 ± 1.9 17 ± 3.5 26 $4-OH$ 88 ± 4.1 46 $3-OCH_3$, $4-OCH_3$ >100nt27 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	24	3-F	75 ± 3.4	44	2-Cl, 4-Cl	19 ± 0.5	23 ± 3.8
26 4-OH 88 ± 4.1 46 $3-OCH_3, 4-OCH_3 > 100$ nt 27 $4-OCH_3$ 67 ± 6.0 $5-OCH_3$ 44% inhibition	25	3-Cl	36 ± 1.9	45	3-Cl, 5-Cl	23 ± 1.9	17 ± 3.5
4-OCH ₃ 67 ± 6.0 5-OCH ₃ 44% inhibition	26	4-OH	88 ± 4.1	46	3-OCH ₃ , 4-OCH ₃	>100	nt
	27	4-OCH ₃	67 ± 6.0		5-OCH ₃	44% inhibition	

Table 2. Cytotoxicities of lignano-9,9'-lactone derivatives **5-46** bearing different kindsof substituents on the 7-atomatic ring against HL-60 and HeLa cells (nt: not tested)

derivatives bearing many kinds of the substituents on the aromatic rings. Because of the results of the activity tests of (8R,8'R)- and (8S,8'S)-matairesinol (2 and 3), we decided to select the (8R,8'R)-configuration for the following derivatives.

The derivatives 5-46 bearing many kinds of the aromatic rings at the 7-position and the phenyl group without any substituent at the 7'-position were synthesized and their cytotoxicities were examined (Table 2). The activity of the derivative 5 against HL-60 cells, whose benzene rings do not have any substituent, was similar to that of (8R,8'R)-matairesinol (2) in Table 1, suggesting that phenolic hydroxy groups and methoxy groups of matairesinol are not necessary to show this level of The results of the tests of the 2-hydroxy 6, 4-hydroxy 26, 2-methoxy 7, activity. 3-methoxy 17, and 4-methoxy 27 derivatives reflects this fact, showing the same level of the EC₅₀ values (66-88 μ M) as the derivative **5**. The introduction of a hydroxyl group to the 3-position dramatically reduced the activity (16: $EC_{50} > 100 \mu M$, against HL-60 cells). The electron-withdrawing trifluoromethoxy derivatives 8, 18, 28 showed 2-3-fold higher activities than the methoxy derivatives 7, 17, 27 to exhibit the EC_{50} values of 23-40 μ M. Though the activities of the methoxymethoxy derivatives 9, **19**, **29** and heptoxy derivatives **11**, **21**, **31** were similar to those of the methoxy derivatives 7, 17, 27, the butoxy derivatives 10, 20, 30 showed 2-4-fold more potent activities than the methoxy derivatives 7, 17, 27, exhibiting the EC_{50} values of 20-26 μ M. It is suggested that the suitable length of the alkoxy group for the higher activity would be present. Thus, the derivatives bearing the methoxy group and heptoxy group showing lower activities than the butoxy derivatives. Comparing the trifluoromethyl

derivatives 13, 23, 33 with the methyl derivatives 12, 22, 32, the derivatives bearing the higher electron-withdrawing trifluoromethyl group, whose EC₅₀ values were 22-37 μ M, were about 2-fold more potent than the methyl compounds. As for the comparison of the halogen derivatives, the chloro-derivatives 15, 25, 35 were around 2-fold more potent than the fluoro-derivatives 14, 24, 34 to show the EC₅₀ values of 36-37 μ M. The activity levels of the fluoro-derivatives 14, 24, 34 (EC₅₀ = 57-72 μ M) were similar to the phenyl derivative 5, suggesting that the activity is not affected by the density of electron. The di-substituted derivatives were also tested. The activity of the 3-methoxy-4-hydroxy derivative **36** was almost similar to that of mono-hydroxy derivatives, showing activity (EC₅₀ = 93 μ M). However, the activity of the phenolic derivative was increased by the introduction of a longer alkoxy group at the 3-position. The 3-butoxy-4-hydroxy derivative 37 (EC₅₀ = 35 μ M) was 3-fold more potent than the 3-methoxy-4-hydroxy derivative **36**. Though the hydrophobicity seemed to be important for the higher activity, the activities of the 3,4-dimethoxy derivative 38 and 3,4-dibutoxy derivative **39** were very weak ($EC_{50} > 100 \mu M$). On the other hand, the EC_{50} value of the 3,4-methylenedioxy derivative 40 was 57 μ M, which was almost similar to that of the 3,4-difluoro derivative 42 (EC₅₀ = 50 μ M). The 3,4-dimethyl derivative showed higher EC_{50} value of 35 μ M than 40 and 42, suggesting that the presence of the oxygen atoms is disadvantageous and some size of hydrophobic groups is necessary for the higher activity. This assumption was confirmed by the tests using the dihalogen derivatives. The dichloro derivatives 43-45 (EC₅₀ = $19-23 \mu$ M) were 2-fold more potent than the 3,4-difluoro derivative **42**. The 3,4,5-trimethoxy

derivative **46** was not effective. The activity level did not depend on the position of the hydrophobic group on the 7-aromatic ring. Some effective derivatives were applied to HeLa cells. The EC₅₀ values of the 4-butoxy **30**, 4-trifluoromethyl **33**, and dichloro derivatives **43-45** were 17-29 μ M against HeLa cells, showing higher activities than natural (8*R*,8'*R*)-arctigenin (**1**). These activities were similar to that of (8*R*,8'*R*)-dihydroguaiaretic acid (**4**), which is a butane type of natural lignan, against



Figure 2. Cytotoxicities of 9,9'-epoxy (47, 48), lign-7-eno-9,9'-lactone (49, 50), and butane 51 type lignans against HL-60 cells

The effect of main lignan structure on the activity was also examined. Figure 2 shows the cytotoxicities of 9,9'-epoxylignans **47**, **48**, lign-7-eno-9,9'-lactone **49**, **50**, and butane type lignan **51** bearing the 3,4-dichlorophenyl group or 4-butoxyphenyl group at the 7-position against HL-60 cells. The activities of the 9,9'-epoxylignan **48** and butane type lignan **51** were similar to that of the corresponding lignano-9,9'-lactone derivative bearing 3,4-dichlorophenyl or 4-butoxy group, however, the butoxy

derivative of 9,9'-epoxylignan **47** showed 2-fold more potent than corresponding lignano-9,9'-lactone derivative **30**. In this case, carbonyl group of lactone structure does not play an important role. Comparing *Z*-form **49** with *E*-form **50**, *Z*-form showed the higher activity ($EC_{50} = 58 \mu M$), however, the corresponding lignano-9,9'-lactone **30** was 2-fold more potent. It was suggested that the presence of α,β -unsaturated double bond, which is found in the natural lignans,²⁷ would be disadvantageous. The higher activity of *Z*-form suggests that the same direction of 7-aryl group as the carbonyl group is favorable for the higher activity.

To evaluate the effect of the aromatic ring at the 7'-position, the 3,4-dichlorophenyl group was employed for the 7-position. Table 3 shows the results of the cytotoxic assay. In the 2'-position, the alkoxy derivatives **53**-**55** (EC₅₀ = 10-15 μ M) were 2-3-fold more effective than the phenolic **52**, methyl **56**, and fluoro **57** derivatives against HL-60 cells. The 2'-butoxy derivative **55** was most effective among the 2'-derivetives against HL-60 cells, showing the EC₅₀ value of 10 μ M. Among the **3'**-derivativs, the 3'-fluoro derivative **61** showed the highest activity against HL-60 cells (EC₅₀ = 14 μ M). The 3'-hydroxy **58**, 3'-methoxy **59**, and 3'-methyl derivative **60** showed the EC₅₀ values of 22-48 μ M. These facts suggest that the smaller hydrophobic group would be important for the higher activity at the 3'-position. In the case of the 4'-position, the 4'-methyl derivative **64** was around 2-fold more potent than the 4'-hydroxy **62** and 4'-methoxy derivative **63** to show the EC₅₀ value of 19 μ M against HL-60 cells. The disadvantage of the presence of the oxygen atom at the 4'-position was suggested. The test of the relationship between the length of the alkyl

		0 9' 1 8' 2' 3' 7'		9 8 7 7	
	9,9'-lac	tone 52-75 $6^{-5^{\prime}}$	н у	9,9'-epoxy 7	6-99 ^{6' 5'}
R	No.	9,9'-lactone,	EC ₅₀ (µM±SD)	No.	9,9'-epoxy, EC ₅₀ (μM±SD)
		HL-60	HeLa		HL-60
2'-OH	52	33 ± 3.6	nt	76	34 ± 2.7
2'-OCH ₃	53	14 ± 4.3	24 ± 4.0	77	55 ± 12
2'-OCH ₂ CH ₃	54	15 ± 4.1	31 ± 6.7	78	29 ± 9.6
2'-O(CH ₂) ₃ CH ₃	55	10 ± 2.8	>100	79	20 ± 6.9
2'-CH ₃	56	22 ± 4.9	nt	80	21 ± 9.5
2'-F	57	28 ± 4.8	nt 💦	81	51 ± 7.7
3'-OH	58	48 ± 8.4	nt	82	31 ± 4.2
3'-OCH ₃	59	34 ± 1.0	nt	83	73 ± 9.0
3'-CH ₃	60	22 ± 4.3	nt	84	28 ± 5.7
3'-F	61	14 ± 2.4	20 ± 3.2	85	20 ± 2.5
4'-OH	62	37 ± 4.2	nt	86	31 ± 3.9
4'-OCH ₃	63	37 ± 3.4	nt	87	39 ± 6.8
4'-CH ₃	64	19 ± 7.8	nt	88	21 ± 3.3
4'-CH ₂ CH ₃	65	16 ± 2.7	nt	89	26 ± 7.9
4'-(CH ₂) ₃ CH ₃	66	9.4 ± 2.3	27 ± 3.3	90	23 ± 8.6
4'-F	67	14 ± 2.7	19 ± 1.3	91	43 ± 6.1
3'-OCH ₃ , 4'-OH	68	36 ± 5.6	nt	92	21 ± 4.1
3'-OH, 4'-OCH ₃	69	32 ± 8.7	nt	93	33 ± 4.3
3'-OCH ₃ , 4'-OCH ₃	70	24 ± 8.7	nt	94	16 ± 3.1
3'-O(CH ₂)O-4'	71	51 ± 7.8	nt	95	22 ± 3.7
3'-O(CH ₂) ₂ O-4'	72	28 ± 12	nt	96	38 ± 9.1
3'-CH ₃ , 4'-CH ₃	73	16 ± 4.5	nt	97	36 ± 6.3
3'-F, 4'-F	74	25 ± 6.3	nt	98	18 ± 2.1
3'-Cl, 4'-Cl	75	20 ± 4.9	nt	99	16 ± 7.3

Table 3. Cytotoxicities of 3,4-dichlorolignan-9,9'-lactone **52-69** and 9,9'-epoxy derivatives **76-93**(nt: not tested). Arctigenin (1): against HL-60 (EC₅₀ = 12 μ M), against HeLa (EC₅₀ >100 μ M)

chain and the activity showed the 4'-butyl derivative **66** was more potent (EC₅₀ = 9.4μ M) than the methyl derivative **64**. The 4'-fluoro derivative **67** showed almost similar activity to the 4'-butyl derivative **66**. It could be assumed that the longer hydrophobic group is advantageous for the higher activity. To evaluate the effects of two substituents, which are found in the natural compounds, activities of derivatives **68-72** were also examined. There is a possibility that the effect of one substituent is increased and the bulky effects could be also evaluated. Among the 3',4'-disubstituted derivatives, the 3',4'-dimethyl derivative **73** showed the highest activity, showing the EC_{50} value of 16 μ M. The derivatives **68-72** and **74** containing the phenolic and alkoxy substituents or two fluorine atoms were 1.5-3-fold less potent than the 3',4'-dimethyl derivative **73**. The activities of the dichloro-derivative **75** was almost similar to that of the 3',4'-dimethyl derivative **73**. Some size of the hydrophobic group would be more potent in the case of the 3',4'-disubstituted derivatives. The almost similar activities to arctigenin 1 were observed in the 2'-butoxy 55 and 4'-butyl derivative **66** against HL-60 cells. The most less potent 9,9'-lactone structure against HL-60 cells were the 3'-OH 58 and 3',4'-methylenedioxy 71 derivatives, which were 5-6-fold less potent than the 4'-butyl derivative 66. The derivatives 53-55, 61, 66, and **67** were applied to the tests against HeLa cells. Except for the 2'-butoxy derivative **55**, the EC₅₀ values of 19-31 μ M, which were higher than that of arctigenin 1, were shown. Considering the inactive 2'-butoxy derivative 54 and active 4'-butyl derivative 66 against HeLa cells, the presence of oxygen atom would be disadvantageous for the higher activity against HeLa cells in the case of the derivative bearing longer

hydrophobic group on the 7'-aromatic ring. Since natural arctigenin bearing two methoxy groups on 7'-aromatic ring is inactive against HeLa cells, more hydrophobicity would be effective against HeLa cells. The activities of the corresponding 9,9'-epoxy derivatives **76-99** were also evaluated against HL-60 cells. The obvious advantage of the 9,9'-lactone structure was shown in the 2'-methoxy derivative **53**, which was 4-fold more potent than the corresponding 9,9'-epoxy structure **77**. The most effective 9,9'-epoxy structure was the 3',4'-dimethoxy **94** and 3',4'-dichloro derivative **99**, showing the EC₅₀ values of 16 μ M. However, the obvious advantage of the 9,9'-epoxy structure than the 9,9'-lactone was not observed in most of the cases. The lowest activity of the 9,9'-epoxy structure was shown in the 3'-methoxy derivative **83** (EC₅₀ = 73 μ M). The most effective 9,9'-epoxy lignan was 4-butoxy derivative **30** (Figure 2, against HL-60 dells, EC₅₀ = 11 μ M), suggesting that the longer alkoxy substituent on the 7-aryl group and phenyl group without substituent on the 7'-position is advantageous in the case of 9,9'-epoxy structure.

In summary, the novel cytotoxic lignano-9,9'-lactones were developed. Two chlorines on the 7-aromatic ring and 2'-butoxy/4'-butyl group on the 7'-aromatic ring were effective to improve the activity level of arctigenin. In the previous study,⁷ the alkoxy derivatives were synthesized and their activities were evaluated. In our research, the chloro and alkyl derivatives were prepared and they showed almost similar activity to arctigenin against HL-60 cells. On the other hand, their activities against HeLa cells were dramatically improved comparing natural arctigenin. It could be assumed that hydrophobic substituents on the aromatic ring are important for the

activity against HeLa sells. We have showed the effects of aromatic substituents in the other lignan structure on the cytotoxicity by our previous study.^{13,28-30} It was clarified that the substituents on the aromatic ring of the lignano-9,9'-lactone structure effects on the activity in this study. Since many biological activities of lignano-9,9'-lactone have been reported,³¹⁻³⁵ there is a possibility that the new biological activities of these compounds would be discovered.

Acknowledgements

Part of this study was performed at ADRES (Johoku station) of Ehime University. We are grateful to MARUTOMO Co., LTD for financial support.

Supplementary data

Supplementary data associated with this article can be found in the online version.

References and notes

- Umehara, K.; Sugawa, A.; Kuroyanagi, M.; Ueno, A.; Taki, T. *Chem. Pharm. Bull.* **1993**, *41*, 1774.
- 2. Konye, R.; Ress, A. E.; Solyomvary, A.; Toth, G.; Darcsi, A.; Komjati, B.;

Horvath, P.; Noszal, B.; Molnar-Perl, I.; Beni, S. Nat. Prod. Comm. 2016, 11, 1459.

Jiang, X.; Zeng, L; Huang, J.; Zhou, H.; Liu, Y. J. Biochem. Molecular Toxicology
2015, 29, 458.

- 4. Li, A.; Wang, J.; Wu, M.; Zhang, X.; Zhang, H. Eur. J. Pharmacol. 2015, 747, 71.
- 5. Su, S.; Cheng, X.; Wink, M. Phytomedicine 2015, 22, 301.
- 6. Qi, Y.; Dou, D.-Q.; Jiang, H.; Zhang, B.-B.; Qin, W.-Y.; Kang, K.; Zhang, N.;

Dong, J. Planta Med. 2017, 83, 51.

7. Kudou, N.; Taniguchi, A.; Sugimoto, K.; Matsuya, Y.; Kawasaki, M.; Toyooka, N.;

Miyoshi, C.; Awale, S.; Dibwe, D. F.; Esumi, H.; Kadota, S.; Tezuka, Y. Eur. J. Med.

Chem. **2013**, *60*, 76.

8. Lei, M.; Gan. X.; Zhao, K.; Yu, Q.; Hu, L. Bioorg. Med. Chem. Lett. 2015, 25, 435.

Xu, X.; Li, C.; Lei, M.; Zhu, Z.; Yan, J.; Shen, X.; Hu, L. *Bioorg. Med. Chem. Lett.* 2016, 26, 2988.

10. Penalvo, J. L.; Adlercreutz, H.; Uehara, M.; Ristimaki, A.; Watanabe, S. *J. Agric. Food Chem.* **2008**, *56*, 401.

11. Kawahara, S; Iwata, I.; Fujita, E.; Yamawaki, M.; Nishiwaki, H.; Sugahara, T.;

Yamauchi, S.; Akiyama, K.; Kishida, T. Biosci. Biotechnol. Biochem. 2010, 74, 1878.

Yamawaki, M.; Nishi, K.; Nishimoto, S.; Yamauchi, S.; Akiyama, K.; Kishida, T.;
Maruyama, M.; Nishiwaki, H.; Sugahara, T. *Biosci. Biotechnol. Biochem.* 2011, 75,
859.

13. Wukirsari, T.; Nishiwaki, H.; Nishi, K.; Sugahara, T.; Akyama, K.; Kishida, T.; Yamauchi, S. *J. Agric. Food Chem.* **2014**, *62*, 5305.

14. Sibi, M. P.; Liu, P.; Ji, J, Hajra, S.; Chen, J., J. Org. Chem. 2002, 67, 1738.

15. Fischer, J.; Reynolds, A. J.; Sharp, L. A.; Michael, S.; Sherburn, M. S. Org. Lett.,2004, 6, 1345.

- 16. Raffaelli, B.; Wahala, K.; Hase, T. Org. Biomol. Chem. 2006, 4, 331.
- 17. Takano, S.; Ohashi, K.; Sugihara, T.; Ogasawara, K. Chem. Lett. 1991, 203.
- 18. Stacie, S.; Koch, C.; Chamberlin, A. R. J. Org. Chem. 1993, 58, 2725.
- 19. Yamauchi, S.; Hayashi, Y.; Nakashima, Y.; Kirikihira, T.; Yamada, K.; Masuda, T.
- J. Nat. Prod. 2005, 68, 1459.
- 20. Tomioka, K.; Mizuguchi, H.; Koga, K. Chem. Pharm. Bull. 1982, 30, 4304.
- 21. Amancha, P. K.; Liu, H.-J.; Ly, T. W.; Shia, K.-S. Eur. J. Org. Chem. 2010, 3473.
- 22. Momose, T.; Tanabe, G.; Tsujimori, H.; Muraoka, O. *Chem. Pharm. Bull.* **1992**, *40*, 2525.
- 23. Allen, C. F. H.; Spangler, F. W. Org. Synth., Coll. Vol. 3. 203.
- 24. Honda, T.; Kimura, N.; Sato, S.; Kato, D.; Tominaga, H. *J. Chem. Soc., Perkin Trans. I* **1994**, 1043.
- 25. Paliakov, E; Strekowski, L. Tetrahedron Lett. 2004, 45, 4093.
- 26. Venuti, M. C.; Loe, B. E.; Jones, G. H.; Young, J. M. J. Med. Chem. 1988, 31, 2132
- 27. Ayres, D.C.; Loike, J.D. A registry of natural lignans. In Lignans; Cambridge University Press: Cambridge, U.K., 1990; pp 12.
- 28. Yamauchi, S.; Kawahara, S.; Wukirsari, T.; Nishiwaki, H.; Nishi, K.; Sugahara, T.; Akiyama, K.; Kishida, T. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 4923.
- 29. Wukirsari, T.; Nishiwaki, H.; Nishi, K.; Sugahara, T.; Akiyama, K.; Kishida, T.; Yamauchi, S. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 4231.
- 30. Wukirsari, T.; Nishiwaki, H.; Nishi, K.; Sugahara, T.; Akiyama, K.; Kishida, T.;
- Yamauchi, S. Biosci. Biotechnol. Biochem. 2016, 80, 669.

31. Arimoto, M.; Matsuura, S.; Muro, C.; Tsujibo, H.; Matsumura, E.; Yamaguchi, H.; Inamori, Y. *Biosci. Biotechnol. Biochem.*, **1994**, *58*, 189.

32. Yang, Y.-N.; Huang, X.-Y.; Feng, Z.-M.; Jiang, J.-S.; Zhang, P.-C. J. Agric. Food

Chem., 2015, 63, 7958.

33. Su, S.; Cheng, X.; Wink, M. J. Pharmacy and Pharmacology, 2015, 67, 1316.

34. Adfa, M.; Rahmad, R.; Ninomiya, M.; Yudha, S.; Tanaka, K.; Koketsu, M. Bioorg.

Med. Chem. Lett. 2016, 26, 761.

35. Iranshahy, M.; T.-Najaran, Z.; Kasaian, J.; Ghandadi, M.; Emami, S. A.; Asili, J.;

Chandran, J. N.; Schneider, B.; Iranshahi, M. Phytother. Res. 2016, 30, 222.

